Clinical trial · Observational
Real-World Immuno-Radiotherapy for Advanced NSCLC
Real-world Survival Outcomes and the Evaluation of Optimal Strategies for Immuno-Radiotherapy in Advanced Non-Small-Cell Lung Cancer: a Territory-wide Study (OCEANUS Study)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The optimal combination strategy for radiotherapy combined with immunotherapy (iRT) in advanced non-small-cell lung cancer (NSCLC) remains unclear, and there is a lack of real-world data to validate its efficacy. The objective of this study is to confirm the survival benefits of iRT in advanced NSCLC and to identify the optimal combination strategy for its use.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer Non-Small Cell Cancer (NSCLC) | Lung Non-Small Cell Carcinoma | ALIAS | 0.85 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| initial Concurrent iRT | Drug | — | UNRESOLVED |
| initial Sequential iRT | Drug | — | UNRESOLVED |
| RT after discontinuation of ICI | Drug | — | UNRESOLVED |
| RT with maintenance of ICI | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- initial iRT for locally advanced NSCLC
- description
- For unresectable locally advanced NSCLC: definitive thoracic radiotherapy must have been administered as the initial treatment, with immunotherapy initiated within 90 days after RT (Sequential iRT) or concurrently with RT (Concurrent iRT).
- interventionNames
- Drug: initial Sequential iRT
- Drug: initial Concurrent iRT
- label
- initial iRT for de novo metastatic NSCLC
- description
- For de novo metastatic NSCLC: radiotherapy targeting the primary lung tumor or metastatic lesions must have been administered as the initial treatment, with immunotherapy initiated within 90 days after RT (Sequential iRT) or concurrently with RT (Concurrent iRT).
- interventionNames
- Drug: initial Sequential iRT
- Drug: initial Concurrent iRT
- label
- Salvage iRT in post-treatment progressive NSCLC
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * NSCLC patients who received immunotherapy between 2015 and 2021 * For unresectable locally advanced NSCLC: definitive thoracic radiotherapy must have been administered as the initial treatment, with immunotherapy initiated within 90 days after RT or concurrently with RT * For de novo metastatic NSCLC: radiotherapy targeting the primary lung tumor or metastatic lesions must have been administered as the initial treatment, with immunotherapy initiated within 90 days after RT or concurrently with RT * For post-treatment progressive NSCLC: salvage radiotherapy must have been performed during immunotherapy or within 90 days after the cessation of immunotherapy * Age \>= 18 years old Exclusion Criteria: * Patients with multiple primary cancers or a pathological diagnosis of small cell lung cancer * Patients who did not receive radiotherapy or who did not undergo radiotherapy within 90 days before or after immunotherapy
References
Publications (0)
Data not yet available